SDZNY vs VTRS: Which Is the Better Buy in 2026?

Same yardstick, side by side (as of October 2026). Valuation lined up like this is most meaningful for two names in the same corner of the market, which these are. Figures are approximate; verify before investing.

Reading it: VTRS is the cheaper of the two on forward earnings, but cheaper is not the same as better. Pair the valuation with growth (how far the forward P/E sits below the trailing P/E) and risk (beta) before you decide.

The metrics above tell you which is the marginally better business. The bigger risk for most people is not picking the slightly worse stock, it is over-concentrating. SDZNY and VTRS share themes, so owning both, or adding either to what you already hold, can quietly push a large share of your portfolio into one bet.

This is the part a generic comparison page cannot answer, because it depends on what you own. Connect your brokerage and Walnut shows your real, combined SDZNY and VTRS exposure, flags overlap with your existing positions, and tells you if adding one would tip you past a concentration you are comfortable with, read-only by default, with your login staying at your broker. Walnut is not an investment adviser.

Sandoz Group AG makes off-patent medicines: generics, which copy small-molecule drugs once their patents expire, and biosimilars, which are near-copies of complex biologic drugs such as antibodies. It sells about 1,300 medicines, from antibiotics and cough remedies to cancer and immunology treatments, and employs more than 20,000 people. Net sales were $11.1B in 2025. In the first half of 2026 net sales were $5.76B, up 5% at constant currencies: generics brought in $3.89B (67%) and biosimilars $1.88B (33%, up from 29% a year earlier). By region, Europe is the core at $3.13B (54% of first-half sales), followed by International at $1.34B and North America at $1.30B, which was the fastest-growing region at +15% at constant currencies. The ten largest medicines grew 14% combined and made up 35% of sales.

Full SDZNY guide

Viatris was created in November 2020 by merging Mylan with Pfizer's Upjohn business, uniting a large generics and biosimilars operation with a portfolio of well-known, off-patent branded drugs such as Lipitor, Norvasc, Viagra, and EpiPen. It sells across more than 165 countries and reports through a global commercial footprint that spans developed and emerging markets, with a business mix of generics, established brands, and a smaller but growing specialty and pipeline component. Because most of its revenue comes from mature, off-patent medicines, Viatris behaves like a value stock: steady cash generation, a modest valuation multiple, and slow top-line growth rather than the rapid expansion of a patent-protected innovator.

Full VTRS guide

Both fit overlapping themes, but they are not interchangeable. The useful comparison is which set of drivers and risks you want exposure to.

• SDZNY drivers: Biosimilar growth and the Bio100 plan; North America and the denosumab launch.
• VTRS drivers: Cash flow, debt reduction, and the dividend; Pivot from generics giant to specialty and pipeline.

A faster-growing, richer-valued name usually swings harder, so it suits a longer horizon and a higher tolerance for volatility; a steadier, more cash-generative business suits a more conservative or income-minded investor. The honest test is which set of risks you could hold through a drawdown: Price erosion is the constant risk in generics. For VTRS, the biggest risk is structural: most of Viatris's revenue comes from mature, off-patent medicines facing constant price erosion and competition, which has produced years of flat-to-declining sales and makes growth hard to generate.

Growth-minded investors who believe the theme has years to run tend to accept the richer multiple for more upside; value-minded investors lean toward the cheaper forward earnings and steadier profile. Pick SDZNY if you believe its drivers more; VTRS if you believe its. Many investors hold both, but since they share themes, that is a concentrated bet, not diversification. Decide deliberately and check overlap. For the full detail, see the SDZNY and VTRS guides.

SDZNY. Trailing sales of ~$11.6B (2025's $11.1B, less the first half of 2025, plus the first half of 2026) put the company at a bit over 3 times sales. The gap between core and reported earnings is wide this year: core net income was $750M in the first half against reported net income of $109M, with legal provisions, restructuring and separation costs making up most of the difference. Net debt of $3.55B is modest next to roughly $2.4B of annualized core EBITDA. The dividend of CHF 0.80 per share for 2025, up from CHF 0.60, works out to a yield of a little over 1% before Swiss withholding tax. Margin progress toward the 25% to 27% 2030 target is the main thing the valuation is waiting on.

VTRS. Figures are approximate and tied to the asOf date; verify live numbers (current revenue, guidance, adjusted and GAAP EPS, dividend, and debt levels) before acting. Viatris trades on a low multiple typical of a slow-growth value stock, and its adjusted EPS looks much healthier than its GAAP result because large non-cash impairments hit the reported bottom line. The gap between adjusted and GAAP earnings, plus how much of the low multiple reflects genuine value versus stagnant revenue, is the crux of the debate on the stock.

Headline figures (approximate, October 2026): SDZNY shows net sales (ttm to june 2026) ~$11.6B, net sales (h1 2026) ~$5.76B (+5% at constant currencies), core ebitda (h1 2026) ~$1.21B (20.9% margin), core diluted eps (h1 2026) ~$1.71 (reported net income ~$109M); VTRS shows revenue (fy2025) ~$13.9 to $14.3 billion, down from ~$14.7 billion in 2024, partly due to divestitures, fy2026 revenue guidance ~$14.45 to $14.95 billion (reaffirmed), fy2026 adjusted eps guidance ~$2.33 to $2.47, fy2025 gaap result Large net loss (~$3.5 billion) driven mainly by non-cash goodwill impairment.

SDZNY and VTRS are related but distinct: same themes, different businesses and risks. Neither wins in the abstract; the right pick is whichever thesis you actually believe, sized so you are not over-concentrated in one theme. Walnut can show your combined SDZNY and VTRS exposure against your real portfolio. It is not an investment adviser.